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Ppplication of Evidence-Based
edical Therapy Is Associated With
mproved Outcomes After Percutaneous
oronary Intervention and Is a Valid Quality Indicator
issam A. Jaber, MD, Ryan J. Lennon, MS, Verghese Mathew, MD, David R. Holmes, JR, MD,
mir Lerman, MD, Charanjit S. Rihal, MD, MBA
ochester, Minnesota
OBJECTIVES We sought to determine whether the prescription of evidence-based medications at discharge
after successful percutaneous coronary intervention (PCI) can predict long-term clinical
outcome.
BACKGROUND The association of standard-of-care drug utilization and long-term mortality and morbidity
after PCI is not well studied.
METHODS We performed a retrospective cohort study of successful PCI procedures performed on 7,745
patients between March 1, 1998, and December 31, 2004. Discharge medications were
analyzed, and a medication score (MEDS) was developed. A MEDS of 1 was assigned for
each of the following medication classes: 1) antiplatelet, 2) lipid-lowering, 3) beta-blocker,
and 4) angiotensin-converting enzyme (ACE) inhibitor. The outcomes measured were
long-term death, myocardial infarction, and revascularization.
RESULTS Patients with MEDS of 3 to 4 had higher-risk profiles based upon standard clinical and
angiographic criteria. Despite this, at a median follow-up of 36 months, patients with a
MEDS of 3 or 4 were at lower risk of death than those with a MEDS of 0 or 1 (8.9%, 7.5%,
and 13% for MEDS of 4, 3, and 0 to 1, respectively; p  0.014). After adjustment for
covariates, a MEDS of 3 to 4 was associated with significantly lower mortality or myocardial
infarction in follow-up than a MEDS of 0 to 1 (hazard ratios of 0.72 and 0.67 for MEDS
of 3 and 4, respectively; p 0.01). There was no association between MEDS and target vessel
revascularization.
CONCLUSIONS After successful PCI, the use of multiple evidence-based classes of cardiovascular
medications—antiplatelet, lipid-lowering, beta-blockers, and ACE inhibitors—is associated
with improved outcome free of death or MI. (J Am Coll Cardiol 2005;46:1473–8) © 2005
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.070by the American College of Cardiology Foundation
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respite the effect percutaneous coronary intervention (PCI)
as on cardiovascular symptoms, it does not mitigate the
nderlying atherosclerotic process and, more importantly,
oes not prevent death or myocardial infarction (MI) (1).
ntiplatelet therapy, angiotensin-converting enzyme
ACE) inhibitors, beta-blockers, and lipid-lowering therapy
ave each been shown to improve survival and decrease
ardiovascular events in patients with coronary artery dis-
ase, partly by modifying the disease process (2–7). These
lasses form the basis for evidence-based medicine guide-
ines. Despite the beneficial effects these medical therapies
ave on clinical outcome, their use after PCI has not been
niversal (8,9). Whether the extent to which they are
rescribed after PCI can be used as a predictor for clinical
utcome has not been established.
In this study, we sought to define what effect the application
f evidence-based medical therapy in terms of medical treat-
ent after successful PCI has on clinical outcome. We hy-
othesized that a simple medication score (MEDS) based on
From the Mayo Clinic, Rochester, Minnesota.(
Manuscript received March 16, 2005; revised manuscript received June 23, 2005,
ccepted June 27, 2005.he number of cardioprotective medications a patient is dis-
harged on will correlate with improved outcome after PCI.
ETHODS
ata collection. All patients undergoing PCI at the Mayo
linic are prospectively enrolled in a registry that includes
aseline demographic, clinical, and angiographic character-
stics. These patients are contacted 6 and 12 months after
he procedure and yearly thereafter by trained research
echnicians. The supervisor of the data entry technicians
erforms routine audits of the data every one to two months:
ata variables that are out of range are identified, and the
orresponding medical records are reviewed; approximately
0% of all patients in the registry also are selected routinely
or chart review so that the accuracy of the data that were
ut into the database is correct.
After approval by the Mayo Clinic Institutional Review
oard, the PCI registry was searched for all successful PCI
rocedures performed between March 1, 1998, and January
1, 2004, at Saint Mary’s Hospital in Rochester, Minnesota.
hese dates were chosen because our practice remained
elatively stable with regard to adjunctive medical therapies
in particular clopidogrel) and stent types (bare-metal).
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Medical Therapy After Coronary Intervention October 18, 2005:1473–8uccessful PCI was defined as the presence of 50%
esidual stenosis in the treated coronary lesion after dilation
nd the absence of in-hospital death, Q-wave MI, or
oronary artery bypass graft surgery (CABG) immediately
fter the PCI. For patients undergoing two procedures
uring the study period, only the first procedure was
ncluded. Baseline data on the patients were available from
he database, including clinical characteristics, details of the
CI, and medication use. Patients who refused authoriza-
ion for medical record research were excluded, as per the
tate of Minnesota statute.
A MEDS was assigned to each patient based on the
edications at discharge from the hospital. A MEDS of 1
as added for each of the following medication classes:
ntiplatelets (aspirin), beta-blockers, ACE inhibitors, and
ipid-lowering agents. Therefore, a MEDS of 0 means the
atients were discharged on none of these medication
lasses and a MEDS of 4 means they were discharged on all
our of them. The patients were then grouped into four
ategories: 1) MEDS 0 or 1; 2) MEDS 2; 3) MEDS 3; or
) MEDS 4.
Follow-up was achieved through telephone calls at six
onths and then yearly after PCI, in addition to the review
f hospital records. Measured outcomes were death, MI
defined by increase in cardiac biomarkers), CABG, and
arget vessel revascularization (TVR). The study was ap-
roved by the institutional committee on human research.
nalysis. Continuous variables are summarized as mean 
D. Discrete variables are presented as group percentages.
aplan-Meier estimates were used to describe survival rates.
or time-to-event analyses, follow-up began at the date of
ischarge. One-way analysis of variance, Pearson’s chi-
quare test, and the log-rank test were used to test the
ignificance of group differences.
Cox proportional hazards survival models were used to
stimate the hazard ratios for the MEDS. The MEDS
roup 0 to 1 was designated as the reference group.
ovariate models for the three end points (death, death/MI,
nd death/MI/TVR) were built using backward selection on
isk factors significantly associated with the end points in
imple Cox regression models. The three parameters for
EDS effects were then added to the covariate models to
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CABG  coronary artery bypass graft surgery
CHF  congestive heart failure
CI  confidence interval
HR  hazard ratio
MEDS  medication score
MI  myocardial infarction
PCI  percutaneous coronary intervention
TVR  target vessel revascularizationssess the “independence” of these effects. TESULTS
atient population. There were 10,060 PCI procedures
erformed on 8,465 patients. A total of 205 patients denied
uthorization for their records to be used for research. The
arliest PCI for the remaining 8,260 patients were selected
or analysis. Of these, 7,769 were successful PCI proce-
ures. A total of 24 patients did not have enough medica-
ion information to calculate a MEDS, resulting in a final
ample size of 7,745. The median follow up was 36 months.
Only 26 patients had a MEDS of 0; thus, the 0 and 1
EDS groups were combined to form a sample of 507
atients. A total of 1,739 patients had a MEDS of 2, 3,321
ad a MEDS of 3, and 2,178 had a MEDS of 4. The
aseline characteristics of the patients in each of these
roups are shown in Table 1. The angiographic and proce-
ural characteristics are detailed in Table 2. The median
mount of time between the last contact with the patients
nd the time of data analysis was similar between the four
roups, suggesting similar compliance and follow-up. As
ompared with patients with lower MEDS, patients with a
EDS of 4 were more likely to have had a recent MI (50%
or MEDS 4 vs. 13% for MEDS 0 to 1; p  0.01), to
resent with congestive heart failure (CHF) (14% vs. 8%,
 0.01), to have an ejection fraction 40% (14% vs. 7%;
 0.01), and to have comorbid illnesses and coronary
rtery disease risk factors. Coronary lesions also were more
ikely to be complex (type C lesion, presence of thrombus,
nd/or no flow), and PCI was more likely to be an
mergency intervention (29% vs. 10%; p  0.01). Patients
ith a MEDS of 0 generally were older, with more renal
isease and malignancies. The groups were not different in
he number of coronary segments treated and stents in-
erted, and were only slightly different in the extent of their
oronary artery disease on angiography (29% of patients
ith a MEDS of 4 had one-vessel disease vs. 31% of
atients with a MEDS of 0 to 1; 38% vs. 42% for two-vessel
isease; 32% vs. 27% for three-vessel disease; p  0.03).
lthough the use of clopidogrel was less common in the
owest score group, it was similar among the three other
roups.
utcomes. At the end of the follow-up period, there were
total of 667 deaths; 1,045 patients with death or MI; and
,824 with death, MI, CABG, or TVR. Despite the fact
hat the patients with MEDS of 3 and 4 had a higher risk
rofile based on the parameters described in Tables 1 and 2,
heir observed mortality was lower than that of patients with
ower MEDS (8.9%, 7.5%, and 13% for MEDS of 4, 3, and
to 1, respectively, p 0.014; Table 3). After including MI
nd MI/CABG/TVR with death in a composite end point,
he difference between the four groups became nonsignifi-
ant, although there was a trend toward better outcome with
igher scores compared with scores of 0 or 1 (Table 3).
ovariates. Relevant baseline clinical and angiographic
haracteristics were included in a multivariable model.
hese characteristics included age, diabetes, CHF on pre-
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October 18, 2005:1473–8 Medical Therapy After Coronary Interventionentation, history of CHF, peripheral vascular disease,
istory of cardiovascular accident, smoking, renal disease,
alignancy, previous CABG, presence of angina, recent
I, hyperlipidemia, multivessel disease, glycoprotein IIb/
IIa use, use of intra-aortic balloon pump, angiographically
able 1. Baseline Characteristics of Patients Stratified by MEDS
Variable
Score 0 to 1
(n  507) (n
ge, yrs 67.7  12 6
ale gender, % 70
I within 7 days before PCI, % 13
reprocedural shock, % 2
nstable angina, % 60
anadian heart class III or IV, % 54
symptomatic, % 1
tress test done before PCI, % 45
roportion of positive stress tests, % 86
iabetes, % 22
ypertension, % 55
ody mass index 28.3  5.2 2
istory of cholesterol 240, % 47
HF on presentation, % 8
moker, % 16
revious MI, % 30
revious angioplasty, % 19
revious coronary bypass graft, % 9
eripheral vascular disease, % 10
revious cerebrovascular events, % 12
oderate/severe renal disease, % 6
eptic ulcer disease, % 7
alignancy, % 16
ntra-aortic balloon pump use, % 1
jection fraction 40, % 7
ischarged on a clopidogrel, % 88
HF  congestive heart failure; MEDS  medication score; MI  myocardial infa
able 2. Angiographic/procedural Characteristics of Patients Stra
Variable
Score 0 to 1
(n  507)
ultivessel disease, % 69
2/C type lesion, % 75
hrombus in any lesion, % 20
alcium in any stenosis, % 38
ifurcation in any lesion, % 11
lcer in any lesion, % 12
ny lesion ostial, % 18
IMI flow grade 0 or 1, % 15
aximum device size (mm) 3.3  0.5
ype of PCI, %
Elective 41
Urgent 49
Emergency 10
o. of segments treated 1.5
otal no. of vessels treated
1 81
2 17
3 1
otal no. of stents placed 1.5  0.9
P IIb/IIIa use, % 40
IMI flow grade 3 post-procedure, % 97
n-hospital non–Q-wave MI, % 3P  glycoprotein; MEDS  medication score; MI  myocardial infarction; PCI  peromplex lesion, and Thrombolysis In Myocardial Infarction
TIMI) flow grade after procedure.
In this multivariable analysis, many of the baseline clinical
nd procedural characteristics were associated with a worse
linical outcome (Table 4). Although age (hazard ratio
e 2
,739)
Score 3
(n  3,321)
Score 4
(n  2,178) p Value
12 65.8  12 66.2  12 0.001
71 70 0.57
31 50 0.001
3 4 0.001
59 51 0.001
53 46 0.001
5 0.5 0.5 0.14
36 29 0.01
86 86 0.45
23 28 0.001
68 79 0.001
5.4 29.7  5.7 29.9  5.7 0.001
82 88 0.001
9 14 0.001
18 21 0.007
54 69 0.001
23 23 0.06
21 23 0.001
10 11 0.17
11 13 0.010
3 3 0.001
7 6 0.55
10 11 0.004
2 2 0.034
10 14 0.001
95 96 0.001
; PCI  percutaneous coronary intervention.
by MEDS
re 2
1,739)
Score 3
(n  3,321)
Score 4
(n  2,178) p Value
70 71 0.023
78 82 0.001
32 41 0.001
34 33 0.05
13 13 0.55
11 13 0.004
22 21 0.35
21 26 0.001
0.6 3.4  0.6 3.4  0.7 0.008
0.001
35 27
48 44
17 29
.5 1.5 1.5 0.69
0.29
83 84
16 14
1 1
0.9 1.5  0.9 1.5  0.9 0.17
58 64 0.001
96 95 0.08
4 4 0.09Scor
 1
7.5 
69
21
2
61
53
0.
45
88
20
61
9.0 
62
8
17
41
21
16
9
10
3
6
12
1
9
94tified
Sco
(n 
67
75
24
36
12
10
23
18
3.4 
41
48
11
1
83
15
1
1.5 
52
97
3cutaneous coronary intervention; TIMI  Thrombolysis In Myocardial Infarction.
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Medical Therapy After Coronary Intervention October 18, 2005:1473–8HR] 1.03), diabetes (HR 1.42), previous cardiovascular
istory (HR 1.26 for previous MI and 2.27 for CHF), renal
isease (HR 2.05), hypertension (HR 1.19), recent MI (HR
.25), and smoking (HR 1.38) were related to increased risk
f death or MI, elective PCI (HR 0.84) and TIMI flow
rade 3 after PCI (HR 0.69) were associated with a lower
isk. Adjusting for all these factors, a higher MEDS appears
o be related to a decrease in the rate of mortality, although
he results did not reach statistical significance (HR 0.77
nd 0.74 for MEDS 3 and 4, respectively, compared with
EDS 0 to 1, p  0.058). There was, however, a
ignificant decrease in the risk of death or MI associated
ith higher MEDS (HR 0.72 and 0.67 for MEDS of 3 and
, respectively, p  0.01; Table 5). The MEDS 3 and 4
roup MI-free survival curves showed a significant diver-
ence from that of the MEDS 0 to 1 group (Fig. 1).
When TVR was included as an outcome variable, the
djusted effect of a higher MEDS became nonsignificant
p  0.05; Table 5). The MEDS was not associated with a
igher risk of the composite end point of death, MI, or
VR.
Compared with patients without a history of a previous
I, patients with such a history had a considerably higher
able 3. Follow-up Outcomes at 36 Months, Unadjusted
Outcome
Score 0 to 1
(n  507)
Scor
(n  1
eath, % 13.0 10
(95% CI) (16.2–9.8) (11.8–
eath/any MI, % 17.6 15
(95% CI) (21.1–13.9) (17.5–
eath/MI/CABG/TVR, % 29.7 25
(95% CI) (33.9–25.3) (28.2–
ABG  coronary artery bypass grafting; CI  confidence interval; MI  myocard
able 4. Factors Independently Associated With Risk of Death
r MI in a Multivariable Analysis
Factor
Adjusted Hazard Ratio
(95% Confidence Interval)
ge, yrs 1.03 (1.02–1.04)
iabetes 1.42 (1.24–1.62)
istory of congestive heart failure 2.27 (1.97–2.62)
revious coronary bypass surgery 1.66 (1.44–1.90)
eripheral vascular disease 1.50 (1.27–1.76)
revious cerebrovascular event 1.35 (1.16–1.58)
oderate/severe renal disease 2.05 (1.61–2.62)
revious MI 1.26 (1.09–1.45)
alignancy 1.30 (1.10–1.55)
-type lesion 1.16 (1.02–1.32)
ypertension 1.19 (1.03–1.38)
etastatic cancer 2.19 (1.37–3.51)
rophylactic intra-aortic balloon pump use 1.54 (1.09–2.17)
I within 7 days before procedure 1.25 (1.06–1.48)
lective percutaneous coronary
intervention
0.84 (0.73–0.97)
IMI flow grade 3 post-procedure in
all lesions
0.69 (0.53–0.91)
urrent smoker 1.38 (1.15–1.67)MI  myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction.bserved mortality rate (HR 3.4, 95% confidence interval
95% CI] 2.2 to 5.5), higher risk of death or MI (HR 2.9,
5% CI 1.9 to 4.4), and a higher incidence of death, MI, or
VR (HR 1.8, 95% CI 1.3 to 2.6). In a multivariable
nalysis, the effect of having a history of a previous MI on
he outcomes became less pronounced, though still slightly
ignificant (HR 1.74, CI 1.07 to 2.83 for death; HR 1.79,
I 1.17 to 2.72 for death or MI; and HR 1.46, 95% CI 1.04
o 2.03 for death, MI, or TVR).
In patients with a history of a previous MI, the effect of
EDS on outcomes in a multivariate analysis was in
eneral more pronounced than in patients without a history
f MI. The adjusted HR of death or MI for MEDS 4 versus
to 1 was 0.56 (95% CI 0.40 to 0.77) for patients with a
istory of previous MI and 0.79 (95% CI 0.53 to 1.18) for
atients with no history of previous MI. Although the
ifferential effect of MEDS is not statistically significant,
here appears to be a trend towards more benefit derived
rom medical therapy with the former group.
ISCUSSION
he main findings of this study are: 1) patients with MEDS
f 3 or 4, that is, discharged on three or four of the
ardioprotective drug classes after successful PCI, have a
ower observed mortality at 36 months than patients with a
EDS of 0 to 1; 2) in a multivariate analysis, higher
EDS were associated with a lower risk of death or MI;
nd 3) there was no association between medication use at
ischarge and the need for TVR.
A possible implication from our findings is that the use of
MEDS based on the number of cardioprotective medica-
ions used at hospital discharge may be used as a quality
arker after PCI. The more medications from the four
xamined drug classes the patient was prescribed, the lower
he risk of mortality and death or MI during follow up.
able 5. Adjusted Hazard Ratios (95% Confidence Intervals) for
ollow-up Events by MEDS
Group Death or MI
Death, MI, or Target
Revascularization
EDS 0 to 1 1.00 (reference) 1.00 (reference)
EDS 2 0.84 (0.66–1.07) 0.88 (0.73–1.06)
EDS 3 0.72 (0.57–0.91) 0.86 (0.72–1.02)
EDS 4 0.67 (0.52–0.86) 0.85 (0.71–1.03)
Score 3
(n  3,321)
Score 4
(n  2,178) p Value
7.5 8.9 0.014
(8.6–6.4) (10.4–7.3)
13.1 15.6 0.31
(14.4–11.7) (17.5–13.6)
24.9 27.7 0.39
(26.6–23.2) (30.1–25.3)
arction; TVR  target vessel revascularization.e 2
,739)
.2
8.6)
.5
13.6)
.9
23.6)EDS  medication score; MI  myocardial infarction.
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October 18, 2005:1473–8 Medical Therapy After Coronary Interventionorrelation with other studies. Antiplatelet therapy,
CE inhibitors, beta-blockers, and lipid-lowering agents
ave all been shown to improve outcome in patients with
oronary artery disease (2–5,7,10). After PCI, most also have
een shown to reduce adverse cardiovascular outcome, al-
hough no beneficial effect on restenosis has been established.
In the Clopidogrel in Unstable Angina to Prevent Re-
urrent Events (CURE) trial, the long-term administration
f clopidogrel after PCI was associated with a lower rate of
ardiovascular death, MI, or any revascularization (relative
isk, 0.7) (6). In an analysis of the Second Primary Angio-
lasty in Myocardial Infarction (PAMI-2) trial, use of
eta-blockers in patients undergoing primary PCI for acute
I was independently associated with lower six-month
ortality (2). Beta-blockers also were shown to be related to
marked long-term survival benefit after elective PCI (HR
.63 at 1 year) (2). Similarly ACE inhibitors reduced the
ncidence of cardiac death, acute MI, and clinical heart
ailure in patients with stable angina and mildly depressed
jection fraction undergoing invasive revascularization (11).
ther studies have similarly associated the use of statins to
mproved clinical outcomes after PCI (12,13).
In our study, patients with MEDS of 4 had a lower
nadjusted mortality than patients with a lower score
espite the fact that they were on average sicker and had
ore comorbid illnesses. After adjusting for multiple vari-
bles associated with a worse outcome (Table 4), a higher
core predicted a lower risk of death or MI at a median of
hree years of follow-up. The difference between the higher
core groups and the group with MEDS of 0 to 1 starts
ppearing early, and persists through follow up (Fig. 1).
lthough the difference between MEDS 4 and MEDS 3 or
was not statistically significant, there is some trend
igure 1. Kaplan-Meier curve for adjusted myocardial infarction-free
urvival according to medication score (MEDS). Relative to MEDS 0 to 1
urve, the p values for MEDS 2, 3, and 4 curves are 0.15, 0.006, and 0.002,
espectively. The numbers below the curves are the number of patients at
isk for each year of follow-up.bserved in the MI-free survival curves. rffect on TVR. The statistical significance seen in the
omposite outcome of death or MI was lost when TVR was
ncluded in the outcome. The most likely explanation for
his is that these cardioprotective medications do not reduce
linically significant restenosis rate and thus do not affect
VR rate. In fact, a few studies have examined the effect of
CE inhibitors, beta-blockers, and statins on restenosis
fter PCI. In particular, quinapril, carvedilol, pravastatin,
nd fluvastatin all failed in separate studies to prevent or
elay the progression of angiographic restenosis at the target
ite after angioplasty (12–15). Their beneficial effect on
ortality and MI is more likely related to their effect on
he general atherosclerotic disease, which is not limited
o the specific region targeted by the percutaneous
ntervention.
EDS in patients with a history of previous MI. The asso-
iation between medication use and the clinical outcomes is
ore pronounced in patients with a history of previous MI
s opposed to those without such a history. However, the
nteraction is not statistically significant, so it cannot be
olidly concluded that patients with a history of MI consti-
ute the only group in which the MEDS is associated with
utcome. It is possible that sicker patients in general derive
he most benefit from medical therapy.
tudy limitations. This study has limitations inherent to
egistry data. The use of medications after intervention was
ot randomized and, thus, resulted in study groups with
ifferent prognostic characteristics. Although the number of
atients was large enough to allow us to correct for many
linical variables, there may have been some other factors
naccounted for in the patients’ medical history, other
edication use, and angiographic data. However, one
trength of our findings is that the unadjusted risk of death
or the group with MEDS of 4 was lower than that for the
ther groups despite the fact that it generally was a sicker
opulation that otherwise would be expected to have a
igher baseline mortality. It is possible that some of the
atients in the MEDS 0 to 1 group received too few
edications because they were too sick to tolerate them.
owever, on average, this was not the case, as is clearly seen
n Tables 1 and 2.
It was also unknown to us how compliant the patients
ere with the prescribed medications once outside the
ospital. However, this should not affect the implication of
ur data that medication prescription profile at discharge is
inked to the long-term clinical outcome.
onclusions. In summary, this large observational study
emonstrates that positive clinical outcomes after successful
CI are associated with the prescription of evidence-based
edical therapies at discharge.
eprint requests and correspondence: Dr. Charanjit S. Rihal,
irector, Cardiac Catheterization Laboratory, Mayo Clinic, 200
irst Street SW, Rochester, Minnesota 55905. E-mail:
ihal@mayo.edu.
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